Disease Landscape and Forecast 인사이트

This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and…

Clarivate Epidemiology’s coverage of acne comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of acne for each country, as well as…

Clarivate Epidemiology’s coverage of clostridium difficile infection (CDI) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Pancreatic cancer is a difficult-to-treat malignancy, with dismal survival outcomes. First-line treatment of metastatic disease is limited to chemotherapy-based regimens such as FOLFIRINOX and…

Clarivate Epidemiology’s coverage of hereditary angioedema (HAE) comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of HAE for each country,…

Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…

The biosimilar / follow-on insulin sector of the diabetes therapy market is evolving. Eli Lilly / Boehringer Ingelheim’s Abasaglar / Basaglar was the first biosimilar / follow-on insulin glargine…

HIV is a deadly viral infection that impairs cells of the immune system and progressively destroys the body’s ability to fight infections. Availability of multiple therapeutic agents for…

In 2019, sales of branded biologics for respiratory indications reached nearly $1.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029…

In 2019, sales of branded MAb biologics in oncology exceeded $20 billion in the major pharmaceutical markets (United States, EU5, and Japan), and the sales of biosimilars in these regions totaled $…

In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $120 billion in the major pharmaceutical markets under study (United…

In 2020, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $100 billion in the major pharmaceutical markets under study (United…